---
schema_version: "secwatch.filing_event.v1"
accession: "0000883984-26-000040"
form_type: "8-K"
ticker: "ICUI"
cik: "0000883984"
company_name: "ICU MEDICAL INC/DE"
filed_at: "2026-08-06T20:11:02+00:00"
generated_at: "2026-08-06T20:14:46.821080+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# ICU Medical Q2 GAAP EPS $0.76, adjusted EPS $2.37; organic revenue up 6%

## Summary
- GAAP revenue $551.7M (+1% YoY); non-GAAP organic revenue +6% excluding IV Solutions divestiture and FX.
- GAAP net income $19.1M ($0.76 diluted EPS) vs $35.3M ($1.43) in Q2 2025.
- Adjusted diluted EPS $2.37 vs $2.10; adjusted EBITDA $110.0M vs $100.3M.
- GAAP gross margin improved to 43% from 38% YoY.
- FY2026 guidance updated; specific numbers not available in provided excerpt.

## SEC filing metadata
- accession: 0000883984-26-000040
- form_type: 8-K
- ticker: ICUI
- cik: 0000883984
- company_name: ICU MEDICAL INC/DE
- filed_at: 2026-08-06T20:11:02+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883984/000088398426000040/0000883984-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883984/000088398426000040/icui-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000883984-26-000040
- JSON: https://secwatch.observer/filing/0000883984-26-000040.json
- Plain text: https://secwatch.observer/filing/0000883984-26-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.